Company intelligence / Profile preview

VIRxSYS

Gaithersburg, Maryland, United Statesbiospace.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

VIRxSYS completed Phase I clinical trials for VRX496 (HIV gene therapy) showing safety and tolerability with stable or decreased viral load in patients. Phase II trials were underway as of 2007 with preliminary results expected by mid-2007.

Therapeutic areas: HematologyRare DiseasesInfectious Diseases
Modalities: Gene therapyRNA therapeuticsLentiviral vectors
Industry: Biotech

Drug pipeline

1 asset

lexgenleucel-T

Discontinued

Beyond the preview

Go deeper on VIRxSYS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIRxSYS.

Explore the full profile